Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 14, 2017

RiboQuark starts enrolment in Phase II/III trial of QPI-1007 in China

Kunshan RiboQuark Pharmaceutical Technology has started patient enrolment in a Phase II/III clinical trial (QRK207) of ocular neuroprotectant QPI-1007 to treat non-arteritic ischemic optic neuropathy (NAION) in China.

Kunshan RiboQuark Pharmaceutical Technology has started patient enrolment in a Phase II/III clinical trial (QRK207) of ocular neuroprotectant QPI-1007 to treat non-arteritic ischemic optic neuropathy (NAION) in China.

QPI-1007 is a synthetic small interfering RNA (siRNA) being developed to temporarily inhibit expression of the Caspase 2 pro-apoptotic protein.

The randomised, double-masked, sham-controlled Phase II/III trial is designed to evaluate the effect of QPI-1007 multi-dose intravitreal injections on visual function in a total of 465 patients with acute NAION.

QRK207 will compare the safety and efficacy of two doses of QPI-1007 over 12 months at about 90 hospitals across several countries such as China, US, Israel, Germany, Australia, Italy and India.

RiboQuark chairman Liang Zicai said: “RiboQuark is committed to developing innovative therapies that address unmet medical needs, and the initiation of the Phase II/III study investigating QPI-1007 in NAION in China is an important step towards this goal.

“RiboQuark is committed to developing innovative therapies that address unmet medical needs.”

“China has a significant NAION patient population, and we are pleased to be the first in the country to provide a siRNA-based therapy that is likely to benefit many patients in need, and to have the first patient ever dosed on a siRNA trial in China.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

RiboQuark is established as a Chinese-foreign equity joint venture between Suzhou Ribo Life Science and Quark Pharmaceuticals.

Quark obtained the China Food and Drug Administration (CFDA) for conducting the QRK207 trial in partnership with Neuro-Ophthalmology Research Disease Investigator Consortium.

QPI-1007 is reported to have demonstrated safe neuroprotective activity in NAION patients in a previous open label, single-dose, dose escalation Phase I trial at 16 US centres and five Israeli sites.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU